Inhaled drug developer Savara Pharmaceuticals has announced the appointment of former Edgemont Pharmaceuticals CFO David L. Lowrance as its new Chief Financial Officer. Savara cited Lowrance’s experience leading IPOs for Acucela, where he was CFO and Secretary, and Cumberland Pharmaceuticals, where he was VP and CFO.
Savara Chairman and CEO Rob Neville commented, “David compliments our team with a strong track record and deep private and public company experience. He will be invaluable as we focus on bringing our two late-stage orphan drugs to market. We are proud to have him on board.”
In June 2016, Savara announced that it would acquire Serendex and its inhaled molgramostim for the treatment of pulmonary alveolar proteinosis (PAP). A Phase 3 trial of the company’s AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis patients is expected to begin in 2017, funded by a recent $20 million financing round.
Read the Savara Pharmaceuticals press release.
